1. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study / V. Leimane [et al.] // Lancet. - 2005. - Vol. 365, N 9456. - Р. 318-326. https://doi.org/10.1016/s0140-6736(05)17786-1
2. Global tuberculosis report 1997-2021 [Electronic resource] // World Health Organization. - Mode of access: https://www.who.int/tb/publications/global_report/en. - Date of access: 01.06.2022.
3. Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases / K. Li [et al.] // J. Med. Chem. - 2014. - Vol. 57, N 7. - P. 3126−3139. https://doi.org/10.1021/jm500131s
4. Лахвич, Ф. Ф. Рациональный дизайн модели ациклических аналогов гидроксиизонипекотиновых кислот / Ф. Ф. Лахвич, П. Ю. Зущик, А. Ф. Лахвич // БГМУ в авангарде медицинской науки и практики. - Минск, 2019. - Вып. 9. - С. 389-399.
5. Лахвич, Ф. Ф. Исследование in silico зависимости структура-активность оксазолидинонов в поиске противотуберкулезных лекарственных средств / Ф. Ф. Лахвич, М. И. Борова, О. Н. Ринейская // БГМУ в авангарде медицинской науки и практики. - Минск, 2022. - Вып. 12, т. 2. - С. 200-205.
6. Thromboembolism in Mycobacterium tuberculosis Infection: Analysis and Literature Review / H. Ha [et al.] // Infect. Chemother. - 2019. - Vol. 51, N 2. - P. 142-149. https://doi.org/10.3947/ic.2019.51.2.142
7. Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin / S. R. Luckner [et al.] // Structure. - 2009. - Vol. 17, N 7. - P. 1004-1013. https://doi.org/10.1016/j.str.2009.04.012
8. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility / G. M. Morris [et al.] // J. Computational Chem. - 2009. - Vol. 30, N 16. - P. 2785-2791. https://doi.org/10.1002/jcc.21256
9. Griffiths, P. A. Mycobacterium terrae: a potential surrogate for Mycobacterium tuberculosis in a standard disinfectant test / P. A. Griffiths, J. R. Babb, A. P. Fraise // J. Hospital Infection. - 1998. - Vol. 38, N 3. - P. 183-192. https://doi.org/10.1016/s0195-6701(98)90273-0
10. Assessment report Xarelto Rivaroxaban [Electronic resource] / European Medicines Agency. - Mode of access: https://www.ema.europa.eu/en/documents/variation-report/xarelto-h-c-944-x-0010-epar-assessment-report-extension_en.pdf. - Date of access: 01.06.2022.